Brief: Intelligent Bio Solutions Completes In-Clinic Portion Of Pharmacokinetic Study
28/06/2024 23:03
June 28 (Reuters) - Intelligent Bio Solutions Inc
INBS.O :
* INTELLIGENT BIO SOLUTIONS- COMPLETES IN-CLINIC PORTION OF
PHARMACOKINETIC STUDY PART OF 510(K) PATHWAY FOR APPROVAL &
COMMENCES REVIEW OF RESULTS
* INTELLIGENT BIO SOLUTIONS INC -CO EXPECTS TO COMPLETE THE
FULL
PK STUDY IN THE THIRD CALENDAR QUARTER OF 2024
Source text for Eikon: ID:n0001493152-24-025644
Further company coverage: INBS.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Intelligent Bio Solutions
See all newsBrief: Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth Of 38% Year-Over-Year, Driven By Reader Installed Base And High-Margin Cartridge Growth
Brief: Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance And Planned US Market Entry
Intelligent Bio Solutions Q3 revenue rises 46%, gross margin tops 50%
Intelligent Bio Solutions rise after clearing security tests ahead of FDA filing
Brief: Intelligent Bio Solutions Completes Clinical Cut-Off Study